ClinicalTrials.gg
RecruitingNCT04042155MACACODUpdated Feb 28, 2024

Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)

An observational study in Atrial Fibrillation and Recurrent Venous Thromboembolism, sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2019; still recruiting 7 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 247 studies in Atrial Fibrillation with a site in Spain — 53 open to participants now, 76 under way, 3 of them phase 3. Atrial Fibrillation · Spain.

Planned enrollment
17th of 85
1,600 · median 500
Started
2019
with 22 others
Observational
85 of 247
15 open now
Primary completion
2024-08
later than 7 of 75 live
Registered
135th of 247
by date

Among the 247 studies in Atrial Fibrillation with a site in Spain, this one is the 17th largest by planned enrollment of the 85 observational ones that give a count, is one of 23 that started in 2019, is one of 85 observational ones, reaches primary completion later than 7 of the 75 other live ones, and was the 135th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

53 of the 247 studies in Atrial Fibrillation with a site in Spain are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies in Atrial Fibrillation with a site in Spain, or all of them as a file.
02

Study summary

MACACOD is a clinical record in the usual clinical practice of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Design: single-center, observational, prospective, uncontrolled study of anticoagulated patients with any direct oral anticoagulant (DOAC) with atrial fibrillation or venous thromboembolism to determine the incidence of serious complications (thromboembolic or hemorrhagic) in real life

Read the detailed description

Population: Patients over 18 years of age, with recurrent atrial fibrillation or venous thromboembolism, already anticoagulated with any DOAC or patients who initiate therapy with DOAC and who give their consent. Upon entering the study, demographic data, previous anticoagulant treatments, previous serious complications, comorbidities and baseline analytical results are recorded. The risk scores CHA2DS2-Vasc, HAS-BLED and Charlson comorbidity index (CCI) are calculated. The type of health education received in relation to anticoagulant therapy is also recorded. During the follow-up, complications and clinical changes and the analytical results of coagulation, renal and hepatic function will be recorded. The risk scores will be updated at each visit. In case of serious complications, the associated costs will be estimated.

03

Conditions studied

  • Atrial Fibrillation
  • Recurrent Venous Thromboembolism

Keywords

  • dabigatran
  • rivaroxaban
  • apixaban
  • edoxaban
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients under treatment with DOAC controlled at the Hospital de Sant Pau in Barcelona and in their area of influence (Primary Care Centers). These patients must be older than 18 years, with atrial fibrillation or recurrent venous thrombosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients older than 18 years.
  • With atrial fibrillation or recurrent venous thrombosis.
  • In chronic treatment with any DOAC type drug.
  • Patients who sign the

Exclusion criteria

Exclusion Criteria:

  • Patients who do not guarantee collaboration.
  • Patients with advanced cognitive impairment and not supervised.
  • Patients with alcoholism.
  • Patients with psychiatric disorder and not supervised
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,600 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Interventions

  • Drugdabigatran, rivaroxaban, apixaban or edoxaban

    Record of all serious complications associated with any of the drugs and the clinical changes that occurred during prospective follow-up.

    Also known as: Pradaxa, Xarelto, Eliquis or Lixiana

06

What researchers measure

Primary outcomes

  1. Thromboembolic events

    Any documented embolic stroke, peripheral arterial embolism or venous thromboembolism

    Time frame: 3 years

  2. Major haemorrhagic events

    Any documented bleeding event grade 3 or 5 in the Bleeding Assessment Research Consortium (BARC) scale Full scale name: Bleeding Assessment Research Consortium Scale ranges: 0-5 Where 0 is the better result and 5 is the worst

    Time frame: 3 years

Secondary outcomes

  1. Other thrombotic events

    Myocardial infarction, transient ischemic attack, superficial thrombophlebitis

    Time frame: 3 years

  2. Clinically (non major) relevant bleeding

    Any documented bleeding event grade 2 in the Bleeding Assessment Research Consortium (BARC) scale Full scale name: Bleeding Assessment Research Consortium Scale ranges: 0-5 Where 0 is the better result and 5 is the worst

    Time frame: 3 years

  3. Mortality

    Death from any cause

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Aug 2024, 61 months after the start.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 61 months is above that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2019
First posted
Aug 1, 2019
StartActual
Jul 29, 2019
Primary completionEst.
Aug 2024
CompletionEst.
Aug 2024
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04042155
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Aug 1, 2019
Start date
Jul 29, 2019
Primary completion
Aug 2024 (estimated)
Completion
Aug 2024 (estimated)
Last update
Feb 28, 2024

Study contacts

Juan C Souto, MD, PhD
Contact
jsouto@santpau.cat
34-654633993
Juan C Souto, MD, PhD
principal investigator · Hospital de la Santa creu i Sant Pau - Barcelona

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion